ABVC BioPharma receives $450,000 in licensing payments from OncoX Sep 1, 2025 06:56PM
ABVC BioPharma (ABVC) Announces Strategic Investment of $7.4M at $20/sh Aug 17, 2023 09:20AM
ABVC BioPharma (ABVC) Announces 1-for-10 Reverse Stock Split Jul 24, 2023 12:37PM
ABVC BioPharma, Inc (ABVC) Projects $1M Proceeds From Dietary Supplement Production Jun 20, 2023 08:32AM
ABVC BioPharma's (ABVC) Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia May 22, 2023 08:30AM


May 4, 2023 08:33AM ABVC BioPharma, Inc (ABVC) Receives US Patent Certificate of PDC-1421
Apr 3, 2023 05:37AM ABVC BioPharma (ABVC) Reports FY23, Provides Operational Highlights
Feb 28, 2023 08:31AM ABVC BioPharma, Inc (ABVC) Provides 2023 Pipeline Update
Feb 21, 2023 08:30AM ABVC BioPharma, Inc (ABVC) Receives Australian TGA Approval to Initiate Phase II Study of Vitargus
Sep 23, 2022 08:30AM ABVC BioPharma, Inc (ABVC) Reports ADHD Phase II Part 2 Clinical Study Update, Receives UCSF Institutional Review Board Approval
Sep 13, 2022 08:33AM ABVC BioPharma (ABVC) Issues Letter to Shareholders